Related Experiment Video
Updated: Aug 17, 2025

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack
Erin G Park1, Zachary Silvano1, Grant E Gregory1
1College of Medicine, Alabama College of Osteopathic Medicine, Dothan, USA.
Abstract:
Hereditary angioedema (HAE) is a rare inherited disease that is caused by the inactivation of the C1 esterase inhibitor. In this case report, we present a 51-year-old female previously diagnosed with HAE who tested positive for SARS-Cov-2 (COVID-19). The patient was treated symptomatically. Dexamethasone was used to treat COVID-19 pneumonia. Broad-spectrum antibiotics (vancomycin and meropenem) were utilized to prevent future infection. Although the patient did not experience an acute angioedema attack during her hospital stay, the patient expired due to the exacerbation of COVID-19 pneumonia.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Allergic Reactions
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antihypertensive Drugs: Direct Renin Inhibitors
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

